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Prevalence of gastric mucosal interleukin-1 polymorphisms 
in Kenyan patients with advanced gastric cancer
Kimang’a Nyerere, Shahin Sayed, Gunturu Revathi, Peter Ojwang, Viviene Matiru, Smita Devani, Mahesh Shah, Samuel Kariuki
To the Editor: Helicobacter pylori is the main cause of peptic 
ulceration, distal gastric adenocarcinoma, and gastric 
lymphoma.1 Worldwide, gastric cancer is the second most 
common malignancy in men and women.1 According to data 
from the Nairobi Cancer Registry, gastric cancer is the fourth 
most common malignancy in adult males and the fifth most 
common in adult females. However, this may not represent 
the true situation because of under-reporting of cases. In the 
development of gastric cancer, environmental factors such as 
smoking, diet and, in particular, infection with H. pylori are 
significant.1 Based on epidemiological studies, the International 
Agency for Research on Cancer (IARC) identified H. pylori as 
a ‘group 1 agent (definite carcinogen)’.2 H. pylori infection can 
result in decreased acid secretion with subsequent mucosal 
atrophy and intestinal metaplasia.1 Another precondition for 
mucosal atrophy is autoimmunity against parietal cells, which 
can mimic classic autoimmune gastritis with the presence 
of various autoantibodies in up to 40% of H. pylori-infected 
individuals.1
The occurrence of intestinal metaplasia, for which a 
relationship with gastric cancer is strongly suggested, has 
been demonstrated in approximately 60% of patients with 
H. pylori infection.1 The metaplasia may then progress to 
gastric cancer, especially to tumours of the intestinal type.1 
Findings by Uemura et al. support the importance of these 
histological findings as a precancerous condition in H. pylori-
associated gastritis.3 However, only a minority of H. pylori-
infected patients develop gastric cancer, which underscores 
the notion that the host genetic background could be of critical 
importance.
Data strongly suggest that the susceptibility to infection 
from H. pylori is mainly conferred by genes involved in 
inflammatory processes following colonisation with H. 
pylori.1 Chronic gastritis is characterised by the release of 
pro-inflammatory cytokines such as interleukin-1β (IL-1β) 
or tumour-necrosis factor alpha (TNFα), which are potent 
inhibitors of gastric acid secretion.1 Advanced-stage gastric 
cancer has been repeatedly associated with polymorphisms 
of the IL-1 gene cluster on chromosome 2q, which contains 
3 related genes within a 430 kb region (IL-1A, IL-1B, and 
IL-1RN), encoding for IL-1α , IL-1β, and the endogenous 
receptor antagonist IL-1ra, respectively. It was hypothesised 
that genetic differences within these genes could influence 
the immune response against pathogens such as H. pylori and 
the development of premalignant histological alterations in 
the gastric mucosa.1 In patients with advanced-stage gastric 
cancer, an increased frequency of the IL-1B-31C and IL-1B-511T 
alleles and the uncommon IL-1B-31C/IL-1B-511T haplotype 
was demonstrated. In addition, the IL-1RN*2 allele and the 
homozygous genotype IL-1RN*2/2 were found in increased 
prevalence in gastric cancers.1 Subsequent studies confirmed 
these genetic associations.1 El-Omar et al. genotyped patients 
with gastric cancer according to tumour localisation (cardia 
v. non-cardia) and oesophageal cancers (adenocarcinomas 
v. squamous cell carcinomas) for various polymorphisms of 
genes encoding for pro- and anti-inflammatory cytokines.4 
They described an increased risk for non-cardia gastric cancer 
in carriers of the IL-1B-511T allele, IL-1RN*2 homozygotes, 
carriers of the TNF-A-308A allele and the haplotype IL-10-
1082A/-819T/-592A. The cumulative risk depends on the 
number of high-risk alleles or genotypes per patient.4 A 
previous study confirmed the risk increase for development 
of gastric carcinoma in carriers of multiple proinflammatory 
genotypes.1 The alleles IL-1RN*2 and IL-1B-511T are associated 
with increased synthesis of the proinflammatory cytokine 
IL-1ß, and the allele TNFA-308A results in an increased 
production of the proinflammatory cytokine TNF.1
Patients and methods
The study used 41 archival paraffin-embedded gastric cancer 
tissue blocks obtained in 2007 from endoscopic biopsies and 
gastrectomies. Haematoxylin and eosin-stained slides were 
reviewed and the tumours classified according to the WHO 
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Center for the International Histological Classification of 
Tumors. DNA was extracted using the QIAamp DNA kit. 
The study was approved by the Aga Khan University (East 
Africa) Research and Ethics Committee. The H. pylori status 
was determined by polymerase chain reaction (PCR) using 
the ureA gene according to the method of Miyabayashi 
et al.5 The ureA region was amplified using the following 
primers: 5’-AAGCTTTTAGGGGTGTTAGGGGTTT-3’. 
The IL-1B fragment was amplified using the following 
primers: 5’- TGGCATTGATCTGGTTCATC-3’ and 5’- 
GTTTAGGAATCTTCCCACTT-3’, while the IL-1RN intron 
2 containing a penta-allelic 86-bp tandem repeats (VNTR) 
DNA oligonucleotides 5’-CTCAGCAACACTCCTAT-3’ and 5’-
TCCTGGTCTGCAGGTAA-3’ flanking this region were used as 
primers.
Data analysis
Statistical analysis to determine the relationship between 
variables was performed using the chi-square test with 
p-values less than 0.005 considered as significant. Linear 
regression determined how independent factors predicted the 
outcome of dependent factors.
Results
We analysed 41 gastric biopsy samples that were preserved in 
formalin and embedded in paraffin wax, obtained over a year. 
All the biopsies were of adult Kenyan patients with advanced 
gastric cancer; 31 (76%) were of the intestinal type and 24% 
were of the diffuse ‘signet ring’ type; 26 (63%) were from male 
and 15 (37%) from female patients; their ages ranged from 36 
years to 76 years, with 56% <50 years of age. We screened for 
the frequencies of genotypes and alleles of IL-1B and IL-1RN 
in these cancer tissues. Overall, 19 (46%) patients had IL-1RN 
while 18 (43%) had IL-1B. When analysed, the IL-1RN found 
in the Kenyan gastric cancer population only showed allele IL-
1RN 1*4 (Fig. 1).
In contrast, when IL-1B was analysed by PCR-RFLP 
(restriction fragment length polymorphism) method, it gave 
products that either remained intact (allele 2; IL-1B-511*2) or 
were cut into two fragments of 190 and 114 bp (allele 1; IL-1B-
511*1) (Fig. 2).
The H. pylori gene was present in only 6 of the 41 samples. 
This was expected because, when H. pylori has been present 
for many years and the stomach becomes atrophic and 
hypochlorhydric, the intragastric environment is no longer 
optimal for H. pylori. Competing faecal-type organisms are 
then able to colonise the stomach. Furthermore, H. pylori is 
able to colonise only normal gastric cells, and not those that 
have differentiated into intestinal metaplasia. Therefore, 
H. pylori disappears from the stomach when atrophy and 
intestinal metaplasia supervene. In patients who are most 
likely to develop gastric cancer (those with extensive intestinal 
metaplasia and atrophy) and those already with advanced 
cancer, as in our cases, the serology is often negative and the 
genes will almost always not be detectable by PCR.
No significant relationship was found between age and 
either IL-1RN or IL-1B in gastric carcinoma from Kenyan 
patients; the chi-square test for both was not significant: p=0.9 
for IL-1RN and p=1.0 for IL-1B, against a significance level of 
0.3 and 0.2 respectively. This indicates that these variables are 
probably independent of each other. Similarly, there was no 
relationship between gender and the occurrence of either IL-
1RN or IL-1B. Linear regression also showed that neither age 
nor gender influenced the expression of IL-1RN or IL-1B.
The situation differs, however, concerning the relationship 
between IL-1RN and IL-1B. The large chi-square statistic 
(8.021) and a small significance level (0.005) indicate that it is 
unlikely that these variables are independent of each other. 
Therefore, we concluded that there is a relationship between 
the occurrence of IL-1RN and IL-1B. Linear regression showed 
an R-value of 0.45, which indicates that a great deal of variance 
is shared by IL-1RN and IL-1B. Analysis of variance (ANOVA) 
obtained from the regression F=9.5 appears to indicate that the 
predictor variable IL-1RN is not equal to the dependent factor 
IL-1B, and that the presence of IL-IRN could be used to predict 
the presence of IL-1B.
Fig. 1. Gel electrophoresis with ethidium bromide staining demonstrating allele IL-1RN 1*4.
Lane 1 and lane 13, molecular maker (Gene ruler 100bp DNA ladder plus). Lane 2, H. pylori
positive control. Lane 3 negative control, lanes 4 - 12 represent DNA from the stomachs of
selected cancer patients obtained from paraffin-embedded tissues.

Fig. 1. Gel electrophoresis with ethidium bromide staining demonstrating 
allele IL-1RN 1*4. Lane 1 and lane 13, molecular maker (Gene ruler 100bp 
DNA ladder plus). Lane 2, H. pylori-positive control. Lane 3 negative 
control, lanes 4 - 12 represe t DNA from the stomachs of selected cancer 
patients obtained from paraffin-embedded tissues.
Fig. 2. RFLP analysis of interleukin 1B (IL-1B). A single bp polymorphism at -511 in the
promoter region of the IL-1B was analysed by the PCR-restriction fragment length
polymorphism method. Lane 1 and lane 13, molecular maker (Gene ruler 100bp DNA ladder
plus). Lane 2, H. pylori-positive control. Lane 3 negative control, Lanes 4 - 12 represent DNA
from the stomachs of gastric cancer patients obtained from paraffin-embedded tissues. Lanes 4 -
6, 2 bands representing allele 1 (ILB-511*1). Lanes 7 and 9 - 12, 1 band fragment of allele 2
(IL-1B-511*2).
Fig. 2. RFLP analysis of interleukin 1B (IL-1B). A single bp polymor-
phism at -511 in the promoter region of the IL-1B was analysed by the 
PCR-restriction fragment length polymorphism method. Lane 1 and lane 
13, molecular maker (Gene ruler 100bp DNA ladder plus). Lane 2, H. 
pylori-positive control. Lane 3 negative control. Lanes 4 - 12 represent 
DNA from the stomachs of gastric cancer patients obtained from paraffin-
embedded tissues. Lanes 4 - 6, 2 bands representing allele 1 (ILB-511*1). 
Lanes 7 and 9 - 12, 1 band fragment of allele 2 (IL-1B-511*2).
SCIENTIFIC LETTER
February 2009, Vol. 99, No. 2  SAMJ
97
Discussion
Instrumental in the development of H. pylori-related gastric 
carcinogenesis are some pro-inflammatory cytokines such as 
interleukin 1 beta (IL-1β) and interleukin 1 receptor antagonist 
(IL-1ra). The interleukin-1 (IL-1) gene cluster on chromosome 
2q contains 3 related genes within a 340-kilobase (kb) region, 
IL-1A, IL-1B and IL-1RN, which encodes the pro-inflammatory 
cytokines IL-1α and IL-1β as well as their endogenous 
receptor antagonist IL-1ra respectively.6 IL-1β is up-regulated 
in the presence of H. pylori and is important in initiating and 
amplifying the inflammatory response to this infection. IL-1β 
is also a potent inhibitor of gastric acid secretion. The IL-1RN 
gene has penta-allelic 86-bp tandem repeats (VNTR) in intron 
2, of which the less common allele 2 (IL-1RN*2) is associated 
with a wide range of chronic inflammatory and autoimmune 
conditions. IL-1RN*2 is associated with enhanced IL-1β 
production.6 Carriers of IL-1RN 2/*2 and IL-1B-511 T have been 
reported to be at increased risk of hypochlorhydria and gastric 
cancer.6
We tested the hypothesis that IL-1 genetic polymorphisms 
are circulating in the Kenyan population and that they 
influenced the presence of IL-1B in H. pylori-associated gastric 
cancer. Intron 2 of the IL-1RN gene was detected and amplified 
by PCR. Homozygous genotype IL-1RN1/*4 was found to be 
present. We also observed the IL-1B gene with heterozygous 
genotype IL-1B-511*1 and IL-1B-511*2 in our cases of advanced 
gastric cancer. This is in contrast with reports from elsewhere 
in the world, where IL-1RN 1/*2 has been detected with 
increased frequency.7
Il-Ran Hwang et al. found that carriers of IL-1B-511 T/T 
genotypes, denoting a single band of 155 bp or IL-1RN*2, 
had higher mucosal IL-1β cytokine levels compared with 
non-carriers.6 They also observed that carriers of IL-1RN 
1/*2 had higher mucosal IL-1β levels than those of IL-1RN 
1/*1 consistent with an effect of this polymorphism on 
mucosal IL-1β. Also, IL-1RN 1/*2 carriers have atrophy scores 
approximately 1 point higher than IL-1RN 1/*1 carriers, which 
implies that in IL-1RN 1/*2 carriers atrophy is accelerated such 
that the mucosa are functionally 20 years older than the gastric 
mucosa of IL-1RN 1/*1 carriers.
IL-1RN*2 allele occurs in the Kenyan population at a much 
higher frequency (46.3%), in contrast with reports on Western 
and Asian populations.7 For example, the frequency of the IL-
1RN*2 allele in East Asian countries was lowest (3 - 6%), while 
that of the Thai population was 12%. The frequency in Western 
populations was reported as 22 - 24%.
Our frequency of the IL-1B-511 allele was lower (18%) than 
that reported in the Thai population (34%) but falls within the 
threshold of other populations (15 - 25%).7 These results are 
consistent with the notion that in any population, the dominant 
factor or combination of factors in relation to gastric cancer 
risk among H. pylori-infected individuals will vary and must 
be examined directly. Only 6 of our cases tested positive for 
H. pylori by gene analysis despite the fact that Ogutu et al.8 
reported a prevalence of 80.5% in Kenyan adults presenting 
with dyspeptic symptoms and normal endoscopic findings. 
This anomaly can be explained by the fact that all our cases 
involved advanced carcinomas, and H. pylori is known to 
disappear as atrophy and intestinal metaplasia supervene over 
a prolonged period of infection.9
In conclusion, this pioneer study of genotype 
polymorphisms for interleukin 1 in the Kenyan population 
provides evidence that individuals with IL-1B and IL-1RN 
polymorphisms associated with H. pylori infection have an 
elevated risk of developing gastric cancer. Since it was a pilot 
study, the observed significant association could be a chance 
observation because of lack of complete clinical information 
on the patients whose tissues were used. Our findings require 
confirmation by prospective analysis of a larger sample, 
looking at other related co-factors.
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